Assessing the clinical, humanistic, and economic impact of early cancer diagnosis: a systematic literature review
Open accessThe DOI matches its Crossref record; 105 of the 107 references it cites were found in a registry or an index.
Abstract
Introduction: There is a clear consensus among healthcare providers on the advantages of early cancer detection and treatment. However, no in-depth review has yet fully presented the clinical, humanistic, and economic benefits of early cancer diagnosis compared to late detection across a broad range of tumor types. Methods: A systematic literature review was conducted to determine the clinical, humanistic, and economic benefits of early cancer diagnosis, as opposed to late diagnosis, as reported in non-interventional studies conducted worldwide. Searches were conducted using electronic databases (MEDLINE and Embase), conference repositories and grey literature. Observational studies in adults diagnosed with bladder cancer, gastric cancer, head and neck cancer (HNC), melanoma, non-small cell lung cancer (NSCLC), renal-cell carcinoma (RCC), and triple negative breast cancer (TNBC) were eligible for inclusion if they reported survival, health-related quality of life (HRQoL), healthcare resource utilization and/or costs, according to stage at diagnosis. Identified records were screened and extracted by two independent reviewers, and discrepancies were resolved by a third reviewer. The quality of studies was assessed using the Newcastle-Ottawa scale and the Larg and Moss adapted checklist. Results: Of the 3,159 records identified, 103 studies were included in this review. The general trend showed worse clinical, humanistic, and economic outcomes when patients were diagnosed at a later stage compared to an earlier stage. Patients diagnosed at an earlier stage, had on average, substantially higher survival rates and lower mortality rates across all cancer types and incurred lower resource utilization and costs (with available evidence for patients with NSCLC, TNBC, and HNC), compared to those diagnosed at a more advanced/later stage. Limited evidence on the humanistic burden suggested that with a more advanced stage at diagnosis, patients with bladder cancer experienced reduced HRQoL. Conclusion: Early cancer diagnosis (i.e., cancer diagnosed at earlier stages or with lower grades) was associated with longer survival, improved quality of life and lower healthcare costs and resource utilization compared to diagnosis of cancer at later stages or higher grades, as reported by overall survival (OS) and HRQoL outcomes. These findings emphasize the importance of screening and early detection of cancer to improve outcomes among patients diagnosed with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As melanoma has the highest mortality among skin cancers, particularly when diagnosis is delayed, early detection is crucial to promote public health, reduce economic costs of health care, and improve patient outcomes (180, 181).”
From Diagnostic accuracy of teledermatology for skin diseases: a systematic review and meta-analysis (2026) · cites this paper as [181]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As melanoma has the highest mortality among skin cancers, particularly when diagnosis is delayed, early detection is crucial to promote public health, reduce economic costs of health care, and improve patient outcomes (180, 181).”
From Diagnostic accuracy of teledermatology for skin diseases: a systematic review and meta-analysis (2026) · cites this paper as [181]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01626-4 · Cited by 13,874 · cited 1×
“A systematic review was conducted following the guidelines in the Cochrane Handbook for Systematic Reviews and the Centre for Reviews and Dissemination (28, 29) and was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (30).”
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
Mortality due to cancer treatment delay: systematic review and meta-analysis
Hanna, T. P., King, W. D., Thibodeau, S., Jalink, M., Paulin, G. A., Harvey-Jones, E., O’Sullivan, D. E., Booth, C. M., Sullivan, R., & Aggarwal, A. (2020) · BMJ · doi:10.1136/bmj.m4087 · Cited by 1,742
Crosby, D., Bhatia, S., Brindle, K. M., Coussens, L. M., Dive, C., Emberton, M., Esener, S., Fitzgerald, R. C., Gambhir, S. S., Kuhn, P., et al. (2022) · Science · doi:10.1126/science.aay9040 · Cited by 1,379 · cited 1×
“…at the time of diagnosis varies across cancer types, and despite advances in diagnostic tools, the majority of patients diagnosed with certain cancer types (for example, lung, pancreatic and ovarian cancers) are still detected at an advanced stage, leading to poor prognoses and outcomes (11, 12).”
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302983 · Cited by 1,180
Neal, R. D., Tharmanathan, P., France, B., Din, N. U., Cotton, S., Fallon-Ferguson, J., Hamilton, W., Hendry, A., Hendry, M., Lewis, R., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.48 · Cited by 999
Pulte, D., & Brenner, H. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0289 · Cited by 849
Research works printed but not linked: 7
- 15. Kuznar W. Targeted agents, immunotherapies are advancing to the adjuvant setting in solid tumors. Targeted Therapies Oncol. (2021) 10(12):32.
- 16. National Academies of Sciences Engineering and Medicine. Chapter: 9. Federal programs that support cancer prevention and early detection. In: Fulfilling the Potential of Cancer Prevention and Early Detection. Washington, DC: The National Academies Press; (2003).
- 50. Tulyaeva AB, Iztleuov YM, Balmagambe-Tova SK, Koyshybaev AK, Djussembekov ST, Aitmagambetova MA. Five-year survival in young patients diagnosed with gastric cancer comparing to the older groups in the Aktobe province of western Kazakhstan within 2013-2017. Minerva Medica;. (2019) 110(Suppl. 1; 2):86.30667207
- 80. Kalilani L, Chao J, Hogea C, Stojadinovic A, Giove TJ, Sun X, et al. Recent Estimates of Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) in the US (2010-2020). The International Society for Pharmacoeconomics and Outcomes Research (ISPOR). (2022) 25(1):S4.
- 103. Sieluk J, Haiderali A, Huang M, Yang L, Tryfonidis K, Hirshfield KM. SEER-Medicare study of early-stage triple-negative breast cancer: Real-world treatment patterns, survival, and expenditures 2010 to 2016. J Clin Oncol. (2020) 38(15). doi: 10.1200/JCO.2020.38.15_suppl.e125 · doi:10.1200/jco.2020.38.15_suppl.e125
- 110. Ramond A, Carroll R, Vekeria S, Nordstrom B. Investigating Secular Trends in the Survival of Melanoma Patients in England. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR. Value in Health (2021) 24:S40.
- 121. Aly A, Johnson C, Doleh Y, Shenolikar R, Hussain A. Lifetime costs of urothelial carcinoma by stage at diagnosis. J Managed Care Specialty Pharm. (2019) 25(3a):S31.
Cited by
The Health Impact of Using Anti-PD-1 Agents to Treat Early-Stage Cancer in Belgium
Bento‐Abreu, A., Vandekeere, S., Sönmez, D., Neves, C., Mantaian, T., Ethgen, O., & Aguiar‐Ibáñez, R. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00357-z · Cited by 7
Self-citationDiagnostic accuracy of teledermatology for skin diseases: a systematic review and meta-analysis
Martyin, K., Meznerics, F. A., Bokor, L. A., Szabó, B., Hegyi, P., Kiss, N., & Bánvölgyi, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1739592 · Cited by 4
“As melanoma has the highest mortality among skin cancers, particularly when diagnosis is delayed, early detection is crucial to promote public health, reduce economic costs of health care, and improve patient outcomes (180, 181).”
A cross-sectional assessment of US cancer diagnoses during the COVID-19 pandemic
Burus, T., Kim, U., Rose, J., Koroukian, S. M., & Kuhs, K. A. L. (2025) · Cancer Epidemiology · doi:10.1016/j.canep.2025.102944 · Cited by 3
Rationale and recommendations for improving early-stage oncology diagnosis, treatment, and access
Aguiar‐Ibáñez, R., Goldschmidt, D., Zhou, Z., Eales, J., Peters, S., Cardoso, F., Ciani, O., Arunachalam, A., Haiderali, A., Roediger, A., et al. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2623775 · Cited by 3
Self-citationAkpe, V., & Cock, I. E. (2025) · Preprints.org · doi:10.20944/preprints202509.0304.v1 · Cited by 3
Metadata
- Authors
- Aguiar-Ibáñez, R., Mbous, Y. P. V., Sharma, S., & Chawla, E.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- PAREXEL International (India) (IN)
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2025-03-19
- Volume
- 15
- Pages
- 1546447-1546447
- ISSN
- 2234-943X (ISSN-L)
- PMC
- PMC11962897
- OpenAlex
- W4408621175
- Cited by
- 17
- References
- 107
- Citations by year
- 2026: 13 · 2025: 4
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- early cancer detection, cancer stage at diagnosis, cancer screening, overall survival, health-related quality of life, healthcare resource utilization, health care costs, bladder cancer, gastric cancer, head and neck cancer, melanoma, non-small cell lung cancer, renal cell carcinoma, triple-negative breast cancer, tumor grade
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessing the clinical, humanistic, and economic impact of early cancer diagnosis: a systematic literature review. https://app.cochat.ai/papers/10.3389/fonc.2025.1546447
- The paper
- Aguiar-Ibáñez, R., Mbous, Y. P. V., Sharma, S., & Chawla, E. (2025). Assessing the clinical, humanistic, and economic impact of early cancer diagnosis: a systematic literature review. Frontiers in Oncology. https://doi.org/10.3389/fonc.2025.1546447
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.